Asset Details
Do you wish to reserve the book?
No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial
Do you wish to request the book?
No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial
2021
Overview
Abstract
Background
Silexan is a lavender essential oil with established anxiolytic and calming efficacy. Here we asked whether there is a potential for abuse in human patients.
Methods
We carried out a phase I abuse liability single-center, double-blind, 5-way crossover study in healthy users of recreational central nervous system depressants. They received single oral doses of 80 mg (therapeutic dose) and 640 mg Silexan, 2 mg and 4 mg lorazepam (active control) and placebo in randomized order, with 4- to 14-day washout periods between treatments. Pharmacodynamic measures included validated visual analogue scales assessing positive, negative, and sedative drug effects and balance of effects; a short form of the Addiction Research Center Inventory; and a drug similarity assessment. The primary outcome measure was the individual maximum value on the drug liking visual analogue scale during 24 hours post-dose.
Results
Forty participants were randomized and 34 were evaluable for pharmacodynamic outcomes. In intraindividual head-to-head comparisons of the drug liking visual analogue scale maximum value, both doses of Silexan were rated similar to placebo whereas differences were observed between Silexan and lorazepam and between placebo and lorazepam (P < .001). These data were supported by all secondary measures of positive drug effects and of balance of effects. Differences between placebo and both doses of Silexan were always negligible in magnitude. Moreover, Silexan showed no sedative effects and was not perceived to be similar to commonly used drugs that participants had used in the past.
Conclusions
Silexan did not exhibit any abuse potential in a standard abuse potential detection screen study and is unlikely to be recreationally abused.
Publisher
Oxford University Press
Subject
/ Adult
/ Anti-Anxiety Agents - administration & dosage
/ Anti-Anxiety Agents - pharmacology
/ Central Nervous System Depressants - administration & dosage
/ Humans
/ Oils, Volatile - administration & dosage
/ Oils, Volatile - pharmacology
/ Plant Oils - administration & dosage
/ Substance-Related Disorders - diagnosis
/ Testing
